文献速递心脏核医学放射性药物与辐射防护

18F-GP1 PET显像急性动脉血栓的首次人体I期研究

A phase 1, first-in-human study of 18F-GP1 positron emission tomography for imaging acute arterial thrombosis.
PubMed 文献 · EJNMMI Res · 2019-01-07

本研究为首次人体I期试验,纳入10例有急性动脉血栓证据的患者,注射250 MBq 18F-GP1后行PET/CT动态显像至140分钟。结果显示示踪剂安全耐受,所有患者血栓灶均被检出,注射后120分钟血栓SUV中位数5.0,靶本比中位数3.4。

要点

  • 18F-GP1靶向活化血小板糖蛋白IIb/IIIa受体,可安全用于急性动脉血栓显像。
  • 所有10例患者血栓灶均被检出,120分钟SUV中位数5.0。
  • 血栓摄取在注射后7分钟起保持稳定,20分钟后与血池开始分离。

核心结论

  • 18F-GP1是一种安全且有前景的新型PET示踪剂,可用于急性动脉血栓显像,具有良好生物分布和药代动力学特征。

研究设计与样本

  • 首次人体I期研究,纳入10例有急性动脉血栓症状或14天内接受动脉介入/手术且5天内常规影像证实血栓灶的成人患者。
  • 注射250 MBq 18F-GP1后行全身动态PET/CT显像至140分钟,并分析静脉血浆清除和代谢物。

主要发现

  • 18F-GP1给药及PET/CT操作耐受良好,无药物相关不良事件,所有患者图像质量均满足诊断。
  • 所有患者脾、肾和血池初始摄取高,随后快速清除;血浆未代谢18F-GP1在注射后4分钟达峰,至120分钟下降。
  • 血栓灶摄取在注射后7分钟起保持稳定,20分钟后与血池开始分离;120分钟血栓SUV中位数5.0(范围2.4-7.9),血栓SUV与血池平均活性比值中位数3.4(范围2.0-6.3)。

临床怎么用

  • 18F-GP1 PET/CT有望用于急性动脉血栓的直接显像,图像采集可在注射后120分钟进行以获取稳定血栓摄取。

局限性

  • 样本量小(10例),为首次人体I期可行性研究,尚需更大规模研究验证诊断效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 18F-GP1 is a novel positron emission tomography (PET) tracer that targets glycoprotein IIb/IIIa receptors on activated platelets. The study objective was to explore the feasibility of directly imaging acute arterial thrombosis (AAT) with 18F-GP1 PET/computed tomography (PET/CT) and to quantitatively assess 18F-GP1 uptake. Safety, biodistribution, pharmacokinetics and metabolism were also evaluated. METHODS: Adult patients who had signs or symptoms of AAT or had recently undergone arterial intervention or surgery within 14 days prior to 18F-GP1 PET/CT were eligible for inclusion. The AAT focus was demonstrated by conventional imaging within the 5 days prior to 18F-GP1 administration. Whole-body dynamic 18F-GP1 PET/CT images were acquired for up to 140 min after injection of 250 MBq of 18F-GP1. Venous plasma samples were analysed to determine 18F-GP1 clearance and metabolite formation. RESULTS: Among the ten eligible patients assessed, underlying diseases were abdominal aortic aneurysm with endovascular repair (n = 6), bypass surgery and stent placement (n = 1), endarterectomy (n = 1), arterial dissection (n = 1) and acute cerebral infarction (n = 1). 18F-GP1 administration and PET/CT procedures were well tolerated, with no drug-related adverse events. All patients showed high initial 18F-GP1 uptake in the spleen, kidney and blood pool, followed by rapid clearance. Unmetabolised plasma 18F-GP1 levels peaked at 4 min post-injection and decreased over time until 120 min. The overall image quality was sufficient for diagnosis in all patients and AAT foci were detected in all participants. The 18F-GP1 uptake in AAT foci remained constant from 7 min after injection and began to separate from the blood pool after 20 min. The median standardised uptake value of AAT was 5.0 (range 2.4-7.9) at 120 min post-injection. The median ratio of standardised uptake value of AAT foci to the mean blood pool activity was 3.4 (range 2.0-6.3) at 120 min. CONCLUSIONS: 18F-GP1 is a safe and promising novel PET tracer for imaging AAT with a favourable biodistribution and pharmacokinetic profile. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02864810 , Registered August 3, 2016.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Chae SY, Kwon TW, Jin S, et al. A phase 1, first-in-human study of 18F-GP1 positron emission tomography for imaging acute arterial thrombosis. EJNMMI Res. 2019. PMID: 30617563. doi:10.1186/s13550-018-0471-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。